ADAP Adaptimmune Therapeutics plc

4.57
-0.09  -2%
Previous Close 4.66
Open 4.64
Price To Book 1.73
Market Cap 477886952
Shares 104,570,449
Volume 311,000
Short Ratio
Av. Daily Volume 433,040

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Oral presentation at CTOS November 9, 2017.
NY-ESO T-cell therapy
Synovial sarcoma - cancer
Reported no clinical responses October 2016. Intends to alter dosage to include fludarabine.
NY-ESO T-cell therapy
Ovarian cancer
Phase 1/2 presentation at SITC November 2018.
NY-ESO T-cell therapy
Myxoid round cell liposarcoma (MRCLS)
Updated data at ASH December 2017 - Overall response rate (ORR) at 100 days and one year were 76% and 44%.
NY-ESO T-cell therapy
Myeloma
Phase 1/2 initiated November 2015. Data are due 2017.
NY-ESO T-cell therapy
Non-small cell lung cancer (NSCLC)
Phase 1 data at ESMO noted best response was 4/6 with stable disease.
MAGE-A4
Soild tumors
Dose escalation to Cohort 2 in early 2019.
AFP
Hepatocellular carcinoma
Phase 1 data at ESMO noted no current response.
MAGE-A10
Non-Small Cell Lung Cancer (NSCLC)

Latest News

  1. Should You Worry About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) CEO Salary Level?
  2. Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
  3. Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know
  4. Radius Exceeds 2018 Financial Guidance, Provides Updates
  5. Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
  6. Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
  7. What Percentage Of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Do Insiders Own?
  8. Adaptimmune Announces that Gwen Binder will leave in January 2019
  9. Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
  10. Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT
  11. uniQure Stock Rose 35.7% Yesterday—Here’s Why
  12. What You Must Know About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) Financial Strength
  13. 3 Beaten-Down Biotech Stocks: Can They Bounce Back?
  14. Adaptimmune Therapeutics Worldwide Enters Oversold Territory